Australia and New Zealand Melanoma Trials Group

Australia and New Zealand Melanoma Trials Group
Name	Australia and New Zealand Melanoma Trials Group
Abbreviation	ANZMTG
Formation	1997
Type	Clinical trials cooperative group
Headquarters	Sydney
Region served	Australia; New Zealand
Leader title	Chair

Australia and New Zealand Melanoma Trials Group is a cooperative clinical trials group focused on melanoma research and clinical investigation in Australasia. The group coordinates randomized trials, translational studies, and registry projects that link investigators across academic centres, hospitals, and research institutes. It functions as a network hub connecting oncologists, dermatologists, surgeons, pathologists, and translational scientists working on melanoma therapeutics and prevention.

History

The group was established in 1997 amid growing interest in melanoma therapeutics in the late 20th century, parallel to developments at institutions such as Memorial Sloan Kettering Cancer Center, Royal Marsden Hospital, Peter MacCallum Cancer Centre, MD Anderson Cancer Center, and University of Sydney. Early work aligned with international efforts from European Organisation for Research and Treatment of Cancer, National Cancer Institute, Cancer Research UK, and Cooperative Trials Group for Neuro-Oncology to harmonize trial design. Founding investigators included clinicians affiliated with Royal Prince Alfred Hospital, Prince of Wales Hospital, Auckland District Health Board, and Wellington Hospital who sought to formalize multicentre randomized trials across New South Wales, Victoria (Australia), Queensland, and Auckland. The group’s timeline intersects with landmark events such as the approval of agents from companies like Bristol-Myers Squibb, Amgen, and Roche and with breakthroughs reported at conferences including the American Society of Clinical Oncology and European Society for Medical Oncology.

Organisation and Governance

Governance structures reflect models used by cooperative groups such as Trans-Tasman Radiation Oncology Group and Australasian Gastro-Intestinal Trials Group. A central executive committee comprising clinicians from major centres—St Vincent's Hospital (Sydney), Royal Brisbane and Women's Hospital, Royal Hobart Hospital, Christchurch Hospital—oversees trial selection and prioritization. Scientific advisory panels include representation from academic institutions including University of Melbourne, University of Auckland, University of Otago, and research institutes such as Walter and Eliza Hall Institute and Garvan Institute of Medical Research. Ethics and data safety monitoring follow standards employed by Human Research Ethics Committee frameworks and regulatory agencies like Therapeutic Goods Administration and Medsafe. Operational units coordinate with biostatistics teams at centres such as University of New South Wales and Monash University.

Research Programs and Clinical Trials

The group designs and delivers trials across surgical oncology, medical oncology, dermatology, and translational science. Trial portfolios have included adjuvant therapy studies influenced by pivotal trials at Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, and Netherlands Cancer Institute; neoadjuvant studies informed by investigators from Massachusetts General Hospital and Royal Marsden Hospital; and immunotherapy combination trials following reports from Johns Hopkins Hospital and Mayo Clinic. Studies have examined interferon-era regimens contemporaneous with work at University of California, San Francisco and later immune checkpoint inhibitors first trialled by groups linked to Yale School of Medicine and Stanford University School of Medicine. Translational programs collaborate with genomic centres such as Wellcome Sanger Institute and proteomics laboratories associated with Peter Doherty Institute for Infection and Immunity.

Collaborations and Partnerships

The group partners with national bodies including Cancer Council Australia, Melanoma Institute Australia, and Ministry of Health (New Zealand), and international consortia such as International Skin Cancer Collaborative and trial networks like EORTC and AIDS Clinical Trials Group on protocol harmonization. Industry partnerships have involved pharmaceutical companies such as Novartis, Merck Sharp & Dohme, GlaxoSmithKline, and biotechnology firms that sponsor investigator-initiated and cooperative trials. Collaborations extend to philanthropic organisations including Australian Cancer Research Foundation and Cancer Society of New Zealand for infrastructure and patient recruitment support.

Impact and Contributions

Contributions include generation of practice-informing evidence adopted in guidelines from bodies like Therapeutic Goods Administration-aligned formularies and incorporated into recommendations by Royal Australasian College of Physicians and Australian & New Zealand College of Anaesthetists-relevant perioperative guidance. Outputs have influenced staging and management approaches alongside international consensus statements from organizations such as Union for International Cancer Control and American Academy of Dermatology. The group’s trials contributed data cited at scientific meetings including ASCO Annual Meeting and ESMO Congress and in publications from collaborative centres such as Peter MacCallum Cancer Centre.

Membership and Training

Membership comprises clinicians, nurses, trial coordinators, statisticians, and translational scientists from hospitals including Royal Adelaide Hospital, Royal Perth Hospital, Nepean Hospital, Middlemore Hospital, and universities like Griffith University and University of Canterbury. Training programs and workshops mirror educational activities by Australasian Leukaemia & Lymphoma Group and include Good Clinical Practice courses, protocol development training, and investigator meetings drawing faculty from centres such as Harvard Medical School, University of Oxford, and University of Toronto.

Funding and Resources

Funding sources include competitive grants from agencies such as National Health and Medical Research Council, Health Research Council (New Zealand), philanthropic grants from Melanoma Institute Australia and foundations aligned with St Jude Children's Research Hospital-style fundraising, and industry sponsorship from multinational pharmaceutical companies. Resource infrastructure utilises biobanks and data platforms linked to organisations such as Australian Genomics, Clinical Trials Centre (University of Sydney), and institutional research offices at hospitals like Royal Prince Alfred Hospital.

Category:Medical research institutes in Australia Category:Cancer organisations based in Australia Category:Clinical trial organizations